Providence, RI, September 8, 2004—EpiVax, Inc, a leading provider of protein and
genome analysis services, vaccine components, and vaccine candidates to researchers, government agencies, universities, and pharmaceutical companies, has been awarded a BioDefense Phase I Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), for developing a genome-derived, epitope-driven tularemia (Francisella tularensis) vaccine.

The NIAID/NIH grant award for $859,773 will be used to develop a genome-derived, eptitope-driven tularemia vaccine. In this Phase I project, EpiVax will involve screening animal and human subjects for responses to tularemia epitopes. A novel tularemia vaccine candidate will be developed using molecular biology techniques. “Our unique ability to develop epitope-driven vaccines by screening whole genomes for candidate vaccine component is at the core of this research effort,” said Anne De Groot, M.D., President and CEO of EpiVax. “This is a significant initial validation of our approach to create new and innovative vaccines to address such diseases as HIV, Tuberculosis, West Nile Virus, as well as biodefense threats, such as tularemia.” Epitopes are part of a foreign organism (or its proteins) that is recognized by the immune system and targeted by antibodies and/or T cells.

EpiVax will collaborate with TB/HIV Research Lab at Brown University Rhode Island
Hospital, and the Martha’s Vineyard Hospital on this Phase I project. Brown University’s new transgenic mouse facility will be a significant component of this project. An initial seed-funding grant of $70,000 from Brown University used for developing new strains of “mice with human immune systems” was a critical factor in the development of this research program.

Tularemia, in aerosol form, is considered a possible bioterrorist agent. Persons who
inhale an infectious aerosol would likely experience severe respiratory illness, including life-threatening pneumonia and systemic infection, if they are not treated.

About Tularemia:

According to the Centers for Disease Control and Prevention (CDC), about 200 cases of tularemia in humans are reported each year in the United States. Tularemia is a disease caused by the bacterium Francisella tularensis. Tularemia is typically found in animals, especially rodents, rabbits, and hares. Francisella tularensis is highly infectious. A small number of bacteria (10-50 organisms) can cause the disease. If Francisella tularensis were used as a bioweapon, the bacteria would likely be made airborne. People who inhale the bacteria can experience severe respiratory illness. A “live-attenuated” vaccine for tularemia was used in the past to protect laboratory workers, but this vaccine is not currently available.

For more information on tularemia, please visit: or

About EpiVax:

EpiVax, Inc. is dedicated to merging in vitro immunology research with bioinformatics to generate new vaccines for infectious diseases such as HIV, TB, and hepatitis, new therapeutics for cancer and autoimmune diseases, and new protein therapeutics for treatment of cancer and autoimmune diseases. Epitope mapping, the selection of target peptides from an antigen, is a powerful resource for the development of novel vaccines.

EpIVax research shows that peptides chosen by EpiMatrix™ for synthesis and testing are highly likely to provoke an immune response when presented to T cells. Epitopes are the most concise piece of information required by the T cell to generate an immune response. EpiVax tools and products are improved versions of tools derived from research initially carried out at the TB/HIV Research Laboratory at Brown University.

For more information of EpiVax, please visit